All subjects

Yield10 Bioscience and VISION Bioenergy Oilseeds ink license deal

Yield10 Bioscience and VISION Bioenergy Oilseeds ink license deal
Yield10 Bioscience, Inc. has granted VISION Bioenergy Oilseeds, LLC (VISION), an exclusive three-year global license to certain proprietary varieties of Camelina sativa (Camelina) for the production of feedstock oil for biofuels (photo courtesy Yield10).

In the United States (US), agricultural bioscience company Yield10 Bioscience, Inc. (Yield10) has announced that it has granted compatriot VISION Bioenergy Oilseeds, LLC (VISION), an agricultural company focused on commercial production of ultra-low carbon biofuel feedstock, a global license to certain proprietary varieties of Camelina sativa (Camelina) for the production of feedstock oil for biofuels.

By facilitating the large-scale commercial production of herbicide-tolerant Camelina, this license agreement is intended to empower farmers to capitalize on the growing biofuel market while advancing the decarbonization goals of aviation, maritime, and heavy-duty transport industries.

We believe that VISION is well positioned to support the ramp-up of commercial acres of Camelina and the delivery of feedstock oil to their energy partner for biofuels. With this license in place to our partner VISION providing a path to scale and market our Camelina technology in biofuels, we believe this is the best way to enable the value chain for Camelina as a valuable crop at a very large scale, said Dr Oliver Peoples, CEO of Yield10 Bioscience.

Desirable feedstock

Commercial production of Camelina is currently ramping up in North America as a source of ultra-low carbon feedstock oil for the biofuel industry. In consideration for the license and completion of certain deliverables, VISION will make cash payments to Yield10 totaling US$3 million.

Yield10 will supply VISION with certain spring and winter Camelina varieties including varieties exhibiting herbicide tolerance to spray application of broadleaf herbicide glufosinate and tolerance to soil residual Group 2 herbicides.

Under the license, VISION will have a three-year period of exclusivity to commercialize the licensed traits and varieties for use in biofuels.

Once that period elapses, the license granted to VISION will convert to non-exclusive status worldwide.

Yield10 has done outstanding work developing leading herbicide technology in Camelina, and acquiring these rights and access to seed will enable us to accelerate our commercial activities. Herbicide tolerance is critical to enable a ramp-up in the commercial production of Camelina. With this license, we’ll be able to significantly expand our contract production of Camelina suited for use as a cover crop or in rotation with other commercial crops. In 2024, we plan to sample this herbicide tolerance system with some of our key Camelina growers, while simultaneously building planting seed supply to support a potential commercial launch in 2025, said Don Panter, CEO of VISION.

Develop additional varieties

Yield10 retains the right to sublicense these Camelina traits and varieties, as well as to continue to utilize and develop these Camelina varieties to produce omega-3 oil and other Camelina oil and meal products.

‍Yield10 is a leader in the development of elite Camelina, including herbicide-tolerant varieties.

In November of 2023, USDA-APHIS determined that Yield10’s glufosinate tolerant Camelina as well as its stacked herbicide tolerant Camelina may be planted and bred in the United States in response to two Requests for Regulatory Status Review (RSRs) packages submitted by Yield10.

An application to add Camelina to a glufosinate label is pending with the US Environmental Protection Agency (EPA).

As the scale of production grows, we believe the value of our advanced trait technologies can be accessed through future partnerships or licensing agreements. We plan to intensify our commercial focus on the development of engineered Camelina as a platform for producing and commercializing omega-3 oils building on our recent successful scale-up of the omega-3 Camelina line EPA8 in Chile, for use of the omega-3 oils in aquaculture, animal feed, and human nutrition, ended Dr Oliver Peoples.

Most read on Bioenergy International

Get the latest news about Bioenergy

Subscribe for free to our newsletter
Sending request
I accept that Bioenergy International stores and handles my information.
Read more about our integritypolicy here